Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

키워드

참고문헌 (44)

1. Kim BK, "HBV genotypes : relevance to natural history, pathogenesis and treatment of chronic hepatitis B", Antivir Ther, 16, pp.1169~1186 (2011)
2. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
3. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
4. Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
5. Do Seon Song, "Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial", Clinical and Molecular Hepatology, 27(2), pp.346~359 (2021), 대한간학회[DOI]
6. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
7. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
8. Papatheodoridis GV, "The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B", Hepatology, 66, pp.1444~1453 (2017)
9. Kim BG, "Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir", J Viral Hepat, 25, pp.1565~1575 (2018)
10. Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study", JAMA Oncol, 5, pp.30~36 (2019)
11. Kim SU, "A multicenter study of entecavir vs. tenofovir on prognosis of treatmentnaïve chronic hepatitis B in South Korea", J Hepatol, 71, pp.456~464 (2019)
12. Lee SW, "Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea : a large-scale, propensity score analysis", Gut, 69, pp.1301~1308 (2020)
13. Chang TS, "Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B", Sci Rep, 11, pp.1365~ (2021)
14. Ha I, "Comparison of the ontreatment risks for hepatocellular carcinoma between entecavir and tenofovir : a propensity score matching analysis", J Gastroenterol Hepatol, 35, pp.1774~1781 (2020)
15. Shin JW, "Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir", Dig Dis Sci, 66, pp.1739~1750 (2021)
16. Hsu YC, "Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B", Am J Gastroenterol, 115, pp.271~280 (2020)
17. Oh H, "No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis b virus infection treated with entecavir vs tenofovir", Clin Gastroenterol Hepatol, 18, pp.2793~2802 (2020)
18. Yu JH, "Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir", tenofovir in South Korea, 2018, pp.48, 862~871
19. Lee JH, "The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma", Eur J Intern Med (2021)[DOI]
20. Papatheodoridis GV, "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B", J Hepatol, 73, pp.1037~1045 (2020)
21. Pol S, "Similar 5-year HCC occurrence in tenofovir- and entecavir-treated HBV chronic infection in the French AFEF", ANRS CO22 hepather cohort, 2021, pp.53, 616~629
22. Choi HeeKyoung, "Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea", Journal of Korean Medical Science, 36(14), pp.1~10 (2021), 대한의학회[DOI]
23. Su F, "No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir", Gut, 70, pp.370~378 (2021)
24. Ha Y, "Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate", Sci Rep, 10, pp.13537~ (2020)
25. Choi J, "Tenofovir versus Entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection", Hepatology, 73, pp.661~673 (2021)
26. Zhang M, "Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection", Infect Agent Cancer, 13, pp.19~ (2018)
27. Ge Z, "Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality", Medicine(Baltimore), 99, pp.e21454~ (2020)
28. Chen CH, "Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan-a retrospective study", Am J Cancer Res, 10, pp.3882~3895 (2020)
29. Yip TC, "Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China", Gastroenterology, 158, pp.215~225.e6 (2020)
30. Kim WR, "Risk of incident hepatocellular carcinoma in hepatitis B-infected patients treated with tenofovir disoproxil fumarate versus entecavir : a US administrative claims analysis", Hepatology, 70, pp.302A~303A (2019)
31. Lampertico P, "Is tenofovir superior to entecavir in reducing the risk of hepatocellular carcinoma in chronic hepatitis B? The controversy continues", Gastroenterology, 158, pp.42~44 (2020)
32. Nguyen MH, "Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study", J Infect Dis, 219, pp.10~18 (2019)
33. Hou JL, "Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries", Clin Gastroenterol Hepatol, 18, pp.457~467.e21 (2020)
34. Tseng CH, "Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.1039~1052 (2020)
35. Koike K, "Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients", Hepatol Res, 48, pp.59~68 (2018)
36. Choi WM, "Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 19, pp.246~258.e9 (2021)
37. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
38. Murata K, "Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues : a new potential target for HBV infection", Gut, 67, pp.362~371 (2018)
39. Sato A, "Antitumor activity of IFN-lambda in murine tumor models", J Immunol, 176, pp.7686~7694 (2006)
40. Abushahba W, "Antitumor activity of type I and type III interferons in BNL hepatoma model", Cancer Immunol Immunother, 59, pp.1059~1071 (2010)
41. Dave S, "Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B : a systematic review and meta-analysis", Hepatology, 73, pp.68~78 (2021)
42. Li M, "Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B : a critical systematic review and meta-analysis", Hepatol Int, 14, pp.105~114 (2020)
43. Gu L, "Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients : a systematic review and meta-analysis", J Gastroenterol Hepatol, 35, pp.1467~1476 (2020)
44. Liu H, "Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B : a systematic review and meta-analysis", Liver Cancer, 9, pp.468~476 (2020)